Updates are available Correction dated 2025-04-11
Click to view Correction: https://doi.org/10.1007/s12185-025-03978-2
-
Authors
Ito, Tomoki https://orcid.org/0000-0001-5419-9156
Kamimura, Tomohiko
Kiguchi, Toru
Kato, Koji
Takenaka, Risa
Kobayashi, Mariko
Ito, Ayumi
Sakai, Mizu
Izutsu, Koji
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04198415 at ClinicalTrials.govDocuments that mention this clinical trial
Venetoclax treatment for chronic lymphocytic leukemia/small lymphocytic leukemia in Japan: post-marketing surveillance
https://doi.org/10.1007/s12185-024-03832-x
-
Funding
Funding for this research was provided by:
AbbVie GK
- License Information
-
More Information
Article History
Received: 26 January 2024
Revised: 23 July 2024
Accepted: 6 August 2024
First Online: 21 August 2024
Change Date: 11 April 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s12185-025-03978-2
Declarations
:
: TI has received lecture fees from Bristol-Myers Squibb K.K., Mundipharma K.K., Novartis Pharma K.K., Takeda Pharmaceutical Co. Ltd., AbbVie G.K., Chugai Pharmaceutical Co. Ltd., Ono Pharmaceutical Co. Ltd., Nippon Shinyaku Co. Ltd., SymBio Pharmaceuticals Co. Ltd., CSL Behring K.K., and Sanofi K.K.; and grants and research funds from Bristol-Myers Squibb K.K. and AbbVie G.K. T Kamimura has received lecture fees from Janssen Pharmaceutical K.K., Ono Pharmaceutical Co. Ltd., and AbbVie G.K. T Kiguchi has received lecture fees from Bristol-Myers Squibb K.K., Novartis Pharma K.K., and SymBio Pharmaceuticals Co. Ltd.; grants from Daiichi Sankyo Co. Ltd., SymBio Pharmaceuticals Co. Ltd., Janssen Pharma K.K., and Otsuka Pharmaceutical Co. Ltd.; and consultancy fees from Astellas Pharma Inc. KK has received consultancy fees from AbbVie G.K., AstraZeneca K.K., Celgene K.K., Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Janssen Pharma K.K., Daiichi Sankyo Co. Ltd., Ono Pharmaceutical Co. Ltd., and Novartis Pharma K.K.; and lecture and manuscript fees from Bristol-Myers Squibb K.K., Celgene K.K., Sumitomo Dainippon Pharma Co. Ltd., Janssen Pharma K.K., Kyowa Kirin Co. Ltd., MSD K.K., Mundipharma K.K., Ono Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., AbbVie G.K., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., and Chugai Pharmaceutical Co. Ltd. KI has received research funding from AbbVie G.K., AstraZeneca K.K., BeiGene, Celgene K.K., Chugai Pharmaceutical Co. Ltd., Janssen Pharma K.K., Novartis Pharma K.K., and Yakult Honsha Co. Ltd.; and lecture fees from Janssen Pharma K.K., AbbVie G.K., Novartis Pharma K.K., Celgene K.K., AstraZeneca K.K., and Chugai Pharmaceutical Co. Ltd. RT, MK, AI, and MS are employees of AbbVie G.K.
